We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$11.9M
Cap. Flow
+$29.8M
Cap. Flow %
6.53%
Top 10 Hldgs %
47.78%
Holding
85
New
14
Increased
34
Reduced
11
Closed
24

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$18M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$14.6M
3
VRNA
Verona Pharma
VRNA
+$6.28M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.17M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.11M

Top Sells

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$14M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.84M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$6.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.4M
5
ADCT icon
ADC Therapeutics
ADCT
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
76
Protagonist Therapeutics
PTGX
$8.69B
– –
-146,657
Closed -$6.6M
RLAY icon
77
Relay Therapeutics
RLAY
$4.04B
– –
-419,242
Closed -$2.97M
SLDB icon
78
Solid Biosciences
SLDB
$795M
– –
-457,739
Closed -$3.19M
SRPT icon
79
Sarepta Therapeutics
SRPT
$1.58B
– –
-51,245
Closed -$6.4M
TIL icon
80
Instil Bio
TIL
$48.1M
– –
-10,517
Closed -$708K
YARW
81
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
– –
-1,536
Closed -$144K
XNCR icon
82
Xencor
XNCR
$1.5B
– –
-75,507
Closed -$1.52M
ZVRA icon
83
Zevra Therapeutics
ZVRA
$565M
– –
-350,000
Closed -$2.43M
MTEM
84
DELISTED
Molecular Templates, Inc.
MTEM
– –
-623,838
Closed -$876K
LBPH
85
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-124,353
Closed -$4.14M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Silverarc Capital Management held 85 positions worth $457M, up 2.7% from $445M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $29.8M of net new capital in Q4 2024, opening 14 new positions and adding to 34 existing holdings. Its largest new stake was Pliant Therapeutics: 1,315,601 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $14M trimmed.

  • Silverarc Capital Management's largest Q4 2024 buy was Pliant Therapeutics: 1,315,601 shares worth $17.3M.
  • Silverarc Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $14.6M increase.
  • Silverarc Capital Management's biggest Q4 2024 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $14M.
  • Silverarc Capital Management fully exited Alnylam Pharmaceuticals in Q4 2024, selling an estimated $9.84M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $457M portfolio in Q4 2024.
  • Silverarc Capital Management opened 14 new positions and closed 24 in Q4 2024.
  • Silverarc Capital Management's portfolio value rose 2.7% quarter-over-quarter to $457M.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.